Who are JEMPERLI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tevimbra, Penpulimab kcqx, Unloxcyt, Loqtorzi, Jemperli, Libtayo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dostarlimab-gxly.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

JEMPERLI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JEMPERLI (DOSTARLIMAB-GXLY) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Programmed Death Receptor-1 Blocking Antibody [EPC]. Area: Oncology.

marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 Oncology Live · refreshed every 30 min

Target snapshot

JEMPERLI (DOSTARLIMAB-GXLY) — GLAXOSMITHKLINE. Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
JEMPERLI TARGET	DOSTARLIMAB-GXLY	GLAXOSMITHKLINE	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1
Tevimbra	TISLELIZUMAB	Beigene	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2025-01-01
Penpulimab kcqx	PENPULIMAB	Akeso Biopharma	marketed		Pd-1	2025-01-01
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
Loqtorzi	TORIPALIMAB	Coherus Biosciences Inc	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2024-01-01
Jemperli	DOSTARLIMAB	GSK	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1	2021-01-01
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals	marketed		PD-1	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Programmed Death Receptor-1 Blocking Antibody [EPC] class)

· 1 drug in this class
BEIGENE · 1 drug in this class
BRISTOL MYERS SQUIBB · 1 drug in this class
BRISTOL-MYERS SQUIBB · 1 drug in this class
Beigene · 1 drug in this class
Beijing Tongren Hospital · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Coherus Biosciences Inc · 1 drug in this class
GLAXOSMITHKLINE · 1 drug in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JEMPERLI — Competitive Intelligence Brief. https://druglandscape.com/ci/dostarlimab-gxly. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing